Normal view MARC view ISBD view

Adjuvant therapy in patients with resected poor-risk head and neck cancer

In Journal of Clinical Oncology
Contributor(s): Koch WM | Vermorken JB | e-mail:jacques.bernier@hcuge.ch.Clinique de Genolier,1272 Genolier, Switzerland | Bernier J.
Material type: materialTypeLabelArticleSeries: Vol 24 Issues 17.Publisher: 2006Description: 2629-2635.Subject(s): | Switzerland | Cancer | Head and neck | Adjuvant therapy | DDC classification: In: Journal of Clinical OncologySummary: In patients with locally or regionally advanced head and neck carcinomas, postoperative radiotherapy has historically been the adjuvant therapy applied for patients with prognostically worrisome pathologic features. Any improvement in therapeutic index achieved by adding cytotoxic agents to postoperative radiotherapy remained controversial. However, two recent randomized trials, conducted in parallel in Europe and the United States, produced level I evidence regarding improved efficacy in this setting for the concurrent administration of chemotherapy and radiotherapy. High-dose cisplatin and irradiation can now be considered the standard therapeutic approach for resected poor-risk disease. The presence of positive margins and/or nodal extracapsular spread in the surgical specimens are the subgroups that appear to benefit in the most significant way from the addition of chemotherapy to radiation. Many questions regarding the optimization of adjuvant treatments still remain unanswered, especially wit
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR6623

In patients with locally or regionally advanced head and neck carcinomas, postoperative radiotherapy has
historically been the adjuvant therapy applied for patients with prognostically worrisome pathologic features.
Any improvement in therapeutic index achieved by adding cytotoxic agents to postoperative radiotherapy
remained controversial. However, two recent randomized trials, conducted in parallel in Europe and the United
States, produced level I evidence regarding improved efficacy in this setting for the concurrent administration
of chemotherapy and radiotherapy. High-dose cisplatin and irradiation can now be considered the standard
therapeutic approach for resected poor-risk disease. The presence of positive margins and/or nodal extracapsular
spread in the surgical specimens are the subgroups that appear to benefit in the most significant way
from the addition of chemotherapy to radiation. Many questions regarding the optimization of adjuvant
treatments still remain unanswered, especially wit

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha